TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06072612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SV-BR-1-GM
Description: SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon infiltration of the inoculation site
Description: Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon infiltration of the inoculation site
Description: Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of Physician's Choice
Description: Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
Study: NCT06098599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin hydrochloride liposome injection
Description: Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride liposome injection
Description: Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.
Study: NCT05423262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 5 or 10 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 20 mg/kg administered intravenously over 60 minutes (bi-weekly)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg administered intravenously over 30 minutes (bi-weekly)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg administered intravenously over 30 minutes (bi-weekly)
Study: NCT06527287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Ankle Training for Instablity to Optimize Neuromusculoskeletal outcomes (NATION)
Description: The NATION rehabilitation protocol will serve as the true intervention group. NATION is a 6-week evidence-based chronic ankle instability (CAI) rehabilitation protocol that incorporates neurocognitive exercises. Participants will complete up to 18 unsupervised home sessions and up to 12 supervised sessions. Treatment volume and exercises may vary based on participant progress and study team member guidance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-Based
Description: The Evidence-Based rehabilitation protocol will serve as the active comparator group. The Evidence-Based protocol will be similar to the intervention (i.e., NATION protocol), but the exercises will exclude the neurocognitive tasks. Participants assigned to the Evidence-Based protocol will complete up to 18 unsupervised home sessions and up to 12 supervised sessions over the course of 6-weeks. Treatment volume and exercises may vary based on participant progress.
Study: NCT04280211

Intervention type: OTHER
Intervention: Respiratory Assessment
Description: Spirometric measurement

Intervention type: OTHER
Intervention: Respiratory Assessment
Description: Spirometric measurement

Intervention type: OTHER
Intervention: Vestibular Assessment
Description: Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction

Intervention type: OTHER
Intervention: Vestibular Assessment
Description: Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction

Intervention type: OTHER
Intervention: Balance Assessment
Description: Postural stability

Intervention type: OTHER
Intervention: Balance Assessment
Description: Postural stability
Study: NCT05134727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055
Description: Healthy participants will receive AZD5055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Healthy participants will receive placebo
Study: NCT06532331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475
Description: Specified dose on specified days
Study: NCT05134727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Healthy participants will receive placebo
Study: NCT05573646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: Participants will receive a one-hour online group-based dual-task training session twice a week for 12 weeks, giving a total intervention time of 24 hours. A co-design approach will be adopted to develop the training components in the dual-tasks. For the cognitive training component, arithmetic operation, verbal fluency, and upper limb/ finger movements are included. For the physical training component, we select chair-based exercises are included. A group-based training mode led by a facilitator will be adopted. During the session, participants will be asked to turn on their camera so that they can see and interact with each other. They will also have their audio on as they will have to participate in the cognitive tasks by voicing out their answers.

Intervention type: OTHER
Group type: OTHER
Intervention: Attention Control
Description: Participants will receive eight one-hour online group-based interactive education on health topics other than exercise and cognitive health.
Study: NCT06564155

Intervention type: DEVICE
Intervention: carotid duplex
Description: measure Carotid intima media thickness

Intervention type: DEVICE
Intervention: carotid duplex
Description: measure Carotid intima media thickness
Study: NCT06459128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limbic Care
Description: Limbic Care is an AI-enabled smartphone application that delivers cognitive behavioral therapy (CBT) interventions and psychoeducation to users via an interactive, conversational interface using AI. Participants can choose from three courses (sleep, worry, and low mood) that sets the type of content they will see in the app. For each course, different interventions and psychoeducation material will appear in the to do list section of the app on a fixed schedule. The app also allows users to engage in open-ended conversation with the AI, which serves as an non-interventional, empathetic listener.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Workbook
Description: The digital workbook in PDF format will be provided to participants via the Internet. Participants can choose from three workbooks that each focus on a different topic: sleep, worry, and low mood. Each workbook contains psychoeducation material and CBT intervention worksheets, consisting of text, images, and response boxes to write in (if printed out).
Study: NCT05277831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery Intervention
Description: Participants in the Guided Imagery Intervention receive 6 sessions of a Guided Imagery plus standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to create or revise guided imagery scripts. After the session, coaches record the script as a digital audio file and send to the participant. Participants listen to their audio file every day and practice behavioral skills between sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Control
Description: Participants in the Standard Behavioral Control condition receive 6 sessions of a standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to identify lifestyle changes to support tobacco cessation, and set a schedule for practicing new behavioral strategies. Participants complete exercises in a quit booklet every day and practice behavioral skills between sessions.
Study: NCT06567405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical periodontal treatment
Description: Patients will undergo subgingival scaling employing a Piezoelectric ultrasonic scaler to eliminate local factors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma pen with topical ascorbic Acid
Description: local anesthesia of 2% lignocaine will be administered by infiltration technique in the anterior maxillary region. Microneedling of the mucosa will be performed using dermapen needles, employing an intermittent back-and-forth motion in the anterior maxillary and mandibular region for 30-40 seconds, reaching a depth of 1.5 mm. This will involve the creation of microholes in the gingival tissue using derma pen to enhance the concentration and penetration of the ascorbic Acid through the gingival tissues.
Study: NCT05822024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Pupils' Physical Literacy Intervention
Description: The physical literacy intervention 3PL is based on activities, games, and modifications of the physical education classes to target and enhance pupils' physical literacy.
Study: NCT05341583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
Study: NCT06532331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days
Study: NCT05341583

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
Study: NCT04734236

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: New technique vs Xpert
Description: New technique vs Xpert

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: New technique vs Xpert
Description: New technique vs Xpert
Study: NCT05350358

Intervention type: DEVICE
Intervention: LeMaitre Cardial Dialine II
Description: Surgical treatment for the replacement or bypass with LeMaitre Cardial Dialine II
Study: NCT04671329

Intervention type: DEVICE
Group type: OTHER
Intervention: Affirm Contrast Biopsy procedure
Description: Contrast Enhanced Digital Mammography (CEDM) is an extension of the existing indication for diagnostic mammography with the Selenia Dimensions system and 3Dimensions system. Biopsy targeting can be done on captured contrast enhanced images (scout and stereo pair). The CEDM application shall enable contrast enhanced breast imaging using a dual energy technique. This imaging technique can be used as an adjunct following mammography and/or ultrasound exams to localize a known or suspected lesion. Affirm Contrast Biopsy is intended for patients recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities.
Study: NCT05943158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: myoinositol and folic acid
Description: The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
Study: NCT05903820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol patch
Description: Transdermal patch of estradiol
Study: NCT05927441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragonFly Transcatheter Mitral Valve Repair System
Description: Edge-to-edge repair with DragonFly System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragonFly Transcatheter Mitral Valve Repair System
Description: Edge-to-edge repair with DragonFly System
Study: NCT06358924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potassium nitrate with fluoride
Description: Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of the desensitizing agent recommended by the manufacturer (After Whitening Mousse), once for 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide-amorphous calcium phosphate with fluoride
Description: Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Mi Paste Plus once for 3 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite with fluoride
Description: Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Hydroxyapatite and Fluoride (ReminPro) once for 3 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAMAM-carboxylic acid dendrimer
Description: Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of PAMAM once for 30 minutes.
Study: NCT06167447

Intervention type: OTHER
Intervention: questionnaire and examination
Description: Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.

Intervention type: OTHER
Intervention: questionnaire and examination
Description: Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.
Study: NCT06312098

Intervention type: OTHER
Intervention: remote ischemic preconditioning (RIPC)
Description: After induction of anesthesia, the paired RIPC group took the RIPC intervention on the upper arm in the lateral position. The RIPC intervention was applied using a manual cuff inflator, which consisted of three cycles of 5-min inflation of the blood pressure cuff (to 250 mmHg, or to 50 mmHg higher than the preoperative SBP), followed by 5-min deflation of the cuff. In the no-RIPC group, a blood pressure cuff was also applied on the upper arm but was not inflated.
Study: NCT05242614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Hybrid Mindfulness-based Dementia caregiving program (MBDCP)
Description: The hybrid MBDCP includes 6 weekly 90-minute group-based sessions delivered through a face-to-face (1st, 2nd, and 6th sessions) and online approach (3rd, 4th, and 5th sessions). The online session is designed for self-directed learning. The MBDCP includes different mindfulness practices (e.g., mindful eating, body scanning, and mindful walking), psychoeducation on caregiving, and group sharing, aimed at helping caregivers to develop mindfulness skills through the formal and informal practice of mindfulness, and to integrate these skills into their everyday life. The duration of each session is 90 minutes. Th MBDCP will be delivered by a qualified mindfulness therapist. In the MBDCP's online sessions, the caregivers will watch a teaching video (e.g., a video demonstrating mindfulness practices) through a website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation educational program
Description: This program serves as a control for the social effects of the MBDCP. The brief education program consists of 6 weekly 90-minutes group sessions in which the sessions (1st, 2nd, and 6th) and (3rd 4th 5th) will be delivered through the face-to-face and online approach respectively, with the similar group size of the MBDCP. The education contents include caregiving skills, education on mood, and group sharing. The program will be led by a nurse.
Study: NCT06425393

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urea beath test (UBT)
Description: H. pylori infection will be tested using a 13C-urea breath test Kit for all enrolled family members, following the manufacturer's instructions. The sensitivity and specificity of the assay are both over 95%, according to the manufacturer's introduction.
Study: NCT04944823

Intervention type: OTHER
Intervention: Clinical follow-up for 24 months
Description: Sampling and clinical follow-up for 24 months

Intervention type: OTHER
Intervention: Clinical follow-up for 24 months
Description: Sampling and clinical follow-up for 24 months
Study: NCT04897048

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Incremental exercise test (IET)
Description: Incremental cardio pulmonary exercise test until exhaustion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incremental exercise test (IET)
Description: Incremental cardio pulmonary exercise test until exhaustion

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Constant work rate exercise test (CWRET)
Description: constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Constant work rate exercise test (CWRET)
Description: constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
Study: NCT06533709

Intervention type: DIAGNOSTIC_TEST
Intervention: Radio-score
Description: A score based on the LASSO regression model predicting the R0 resection of the primary debulking surgery of advanced ovarian cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radio-score
Description: A score based on the LASSO regression model predicting the R0 resection of the primary debulking surgery of advanced ovarian cancer.
Study: NCT06533774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audéo Lumity 90-R
Description: This study will be using the Audeo L90-R devices, which are programmed by the hearing care professional (HCP) using Target fitting software version 8.1.
Study: NCT05903820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol patch
Description: Transdermal patch of estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: Transdermal patch of estradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Oral progesterone capsules 100mg/day
Study: NCT06071039

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 3D spacer Fabric Based Mattress
Description: For the patients in the intervention group, the 3D spacer fabric-based mattress was used instead of the operating room theater mattress. The pressure level of the patients was monitored throughout the surgery.
Study: NCT04988165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Description: It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.